Vimi HSCT for multiple myeloma in adults. MACRO platform to support patient registry. HSCT for chronic myeloid leukaemia in adults. Indications and current practice for allogeneic and autologous HSCT for haematological diseases, solid tumours and immune disorders. HSCT for acute lymphoblastic leukaemia in children. Graft versus host disease.
|Published (Last):||8 May 2010|
|PDF File Size:||16.84 Mb|
|ePub File Size:||11.26 Mb|
|Price:||Free* [*Free Regsitration Required]|
Email: ed. Mantle cell lymphoma MCL is an aggressive B-cell lymphoma, which is characterized by the chromosomal translocation t 11;14 q13;q32 and overexpression of cyclin D1 in the vast majority of cases.
Introduction Mantle cell lymphoma MCL is an aggressive B-cell lymphoma, which is characterized by the chromosomal translocation t 11;14 q13;q32 and overexpression of cyclin D1 in the vast majority of cases.
Most patients present with advanced stage disease, often with extra-nodal dissemination, and an unfavourable clinical course. Although a significant proportion of patients with MCL enjoy long-term disease control after auto-HSCT, relapse remains the main cause of treatment failure.
The prognosis of patients with MCL recurrence after auto-HSCT appears to be extremely poor, especially if occurring early after transplant Dietrich et al. In order to prevent these refractory courses, treatment strategies, which effectively reduce the risk of relapse after ASCT, are warranted.
These limited results do not justify a rescue auto-HSCT as reasonable salvage strategy in this situation. Other registry studies and single-centre experiences report similar results Cook et al. Chemotherapy-free salvage treatments are obvious options for these highly refractory patients. Such patients with a low percentage of Kipositive tumour cells might not benefit from an allo-HSCT.
For these patients allo-HSCT should be considered. Mantle cell lymphoma. J Clin Oncol. Biol Blood Marrow Transplant. Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation EBMT.
Ann Oncol. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.
Bone Marrow Transplant. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma MCL Younger : a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med.
Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Mature results of the M. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Patterns of survival in mantle cell lymphoma.
The EBMT Handbook
The EBMT Handbook